BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 4039918)

  • 21. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
    Coiffier B; Khayat D; Misset JL; Votan B
    Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
    Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
    J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
    Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
    J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of combined use of adrenocortical hormones and domperidone as anti-emetics during cisplatin therapy].
    Tanaka T; Nakanishi M; Hirose Y; Mise K; Matsushita T; Yamaoto T; Shirosaki H
    Gan To Kagaku Ryoho; 1985 May; 12(5):1049-55. PubMed ID: 4039553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin].
    Horichi N; Taguchi T; Furue H; Ikeda M; Tsukakoshi S
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):953-60. PubMed ID: 11478144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen.
    Plezia PM; Alberts DS; Kessler J; Aapro MS; Graham V; Surwit EA
    Cancer Treat Rep; 1984 Dec; 68(12):1493-5. PubMed ID: 6542448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Phase I study of a new antineoplastic agent, cis-diamminedichloroplatinum (II)].
    Gan To Kagaku Ryoho; 1982 Jan; 9(1):38-45. PubMed ID: 6892190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M; Kanzaki J
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1095-101. PubMed ID: 9239162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
    Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
    Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of granisetron rescue therapy for nausea and vomiting induced by cancer chemotherapies in urogenital malignant tumor].
    Takigawa H; Naruo S; Kanayama H; Kagawa S; Yokoseki H; Inai T; Sumitani H; Sakurai N; Ogawa I; Akazawa S
    Gan To Kagaku Ryoho; 1996 Jun; 23(7):899-903. PubMed ID: 8678539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on urinary gamma-GTP activities as an indicator of cis-diamminedichloride platinum nephrotoxicity].
    Takahashi T; Yoshida K; Nakame Y; Saitoh H
    Hinyokika Kiyo; 1986 Jun; 32(6):789-94. PubMed ID: 2876605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot phase II study of cis-diamminedichloroplatinum (II) against metastatic gastric cancers.
    Miyamoto K; Yoshida S; Saito D; Shimada Y; Tajiri H; Yamaguchi H; Ohkura H; Yoshino M; Yoshida T; Okazaki N
    Jpn J Clin Oncol; 1990 Jun; 20(2):169-76. PubMed ID: 2370696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer.
    Yagoda A; Watson RC; Kemeny N; Barzell WE; Grabstald H; Whitmore WF
    Cancer; 1978 Jun; 41(6):2121-30. PubMed ID: 657084
    [No Abstract]   [Full Text] [Related]  

  • 40. Mitochondria as a target for combination cancer-chemotherapy.
    Singh G; Moorehead R
    Int J Oncol; 1992 Dec; 1(7):825-9. PubMed ID: 21584623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.